Clinical trials
Phase 4 Ovarian Neoplasms trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
31 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2002 | 1 |
| 2003 | 1 |
| 2004 | 1 |
| 2008 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 3 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 5 |
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 14 |
| Unknown status | 5 |
| Terminated | 4 |
| Not yet recruiting | 3 |
| Recruiting | 2 |
| Withdrawn | 2 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Kaohsiung Medical University Chung-Ho Memorial Hospital | 2 |
| ARCAGY/ GINECO GROUP | 1 |
| Amgen | 1 |
| AstraZeneca | 1 |
| Catholic University of the Sacred Heart | 1 |
| Dartmouth-Hitchcock Medical Center | 1 |
| Duke University | 1 |
| Eli Lilly and Company | 1 |
| European Institute of Oncology | 1 |
| GlaxoSmithKline | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Ovarian Neoplasms | 31 |
| Breast Neoplasms | 7 |
| Lung Neoplasms | 4 |
| Endometrial Neoplasms | 3 |
| Uterine Cervical Neoplasms | 3 |
| Brain Neoplasms | 2 |
| Fallopian Tube Neoplasms | 2 |
| Neoplasms | 2 |
| Recurrence | 2 |
| Uterine Neoplasms | 2 |
Trials
Showing 1 to 25 of 31. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.